Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Exclusion Criteria

• •Patients may not be receiving any other investigational agents within 7 days of registration
• •Patients may not be receiving any medications that are known to prolong QT interval unless reviewed and approved by the principal investigator (PI)
• •Subject may not have had hematopoietic stem cell transplant (HSCT) meeting any of the following:
• •* Is within 2 months of transplant from cycle 1 day 1 (C1D1)
• •* Has clinically significant graft-versus-host disease requiring treatment
• •* Has \>= grade 2 persistent non-hematological toxicity related to the transplant
• •* Donor lymphocyte infusion (DLI) is not permitted \< 30 days prior to study registration
• •Fridericia's corrected QT (QTcF) prolongation \> 470 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome); the QTcF will be calculated as the mean of the 3 electrocardiograms (ECGs) taken at screening
• •* NOTE: The formula used to calculate QTcF can be physician's choice, but it must be used consistently throughout the study
• •* Ongoing or active infection requiring systemic treatment
• •* Symptomatic congestive heart failure (\>= class 3)
• •* Unstable angina pectoris
• •* Cardiac arrhythmia
• •* Psychiatric illness/social situations that would, in the investigator's opinion, limit compliance with study requirements
• •* Known human immunodeficiency virus (HIV) infection
• •* Known John Cunningham virus (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML)
• •* Known clinically active hepatitis A, B, or C infections
• •* NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection may enroll if other laboratory criteria are met; those with HBV surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy for the duration of enrollment in the trial
• •* Second malignancy that requires active treatment
• •* Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints